🇺🇸

Regulatory Compliance

· daily

US SEC Trading Suspension Halt Orders — July 23, 2026

On July 22-23, 2026, five US-listed small-cap and micro-cap companies disclosed regulatory listing challenges, highlighting a concentrated round of Nasdaq compliance failures. The filings reveal two distinct themes: immediate trading suspensions/delistings (Nuvve Holding Corp.) and grace-period remediation efforts (Aprea Therapeutics, Fly-E Group, InspireMD, Shore Bancshares). A critical portfolio-level trend is the prevalence of non-compliance with the $1.00 minimum bid price rule (3 of 5 companies), alongside periodic reporting failures (2 of 5). No insider trading activity was reported by any of the companies, suggesting management may be limited in their ability to signal confidence amid regulatory uncertainty. Forward-looking data shows key catalyst dates through January 2027, creating a defined timeline for potential reversals or further downside. The most material development is Nuvve's imminent suspension and move to OTC Pink, representing a near-certain loss of exchange liquidity. The sector-wide pattern suggests increasing regulatory scrutiny on micro-cap compliance with Nasdaq's quantitative and procedural standards.

5 high priority 5 total filings
· daily

US SEC Trading Suspension Halt Orders — July 22, 2026

Both SunPower Inc. and Purple Innovation, Inc. have received Nasdaq notices regarding non-compliance with the minimum $1.00 bid price requirement, highlighting a severe liquidity and market confidence crisis in the solar and consumer goods sectors. SunPower has a 180-day cure period until January 19, 2027, and may seek an additional 180-day extension by moving to the Nasdaq Capital Market, but faces delisting if unable to cure. Purple Innovation received a Hearings Panel decision granting continued listing subject to demonstrating compliance by July 31, 2026, and executed a 1-for-25 reverse stock split effective July 20, 2026, which brought its stock price to $7.12 per share. The period-over-period data shows no revenue or margin trends available, but the insider activity and capital allocation data are absent, suggesting management may be avoiding signaling. The most critical development is the imminent compliance deadline for Purple Innovation (July 31, 2026), which creates a binary event for its listing status. Portfolio-level patterns indicate that both companies are in distressed situations with high delisting risk, and the market should monitor for potential reverse stock splits or further regulatory actions.

2 high priority 2 total filings
· daily

US SEC Trading Suspension Halt Orders — July 21, 2026

The three filings from July 21, 2026, reveal a concentrated wave of Nasdaq compliance and delisting actions affecting small-cap and micro-cap issuers, signaling heightened regulatory scrutiny on corporate governance, minimum bid price, and foreign issuer disclosures. Notably, two of the three companies face material threats to their listing status, with CN Healthy Food Tech Group Corp. receiving a direct delisting determination tied to CSRC review disclosures, while Cypherpunk Technologies Inc. is in a 180-day cure period for sub-$1.00 bid price non-compliance. Origin Investment Corp I quickly remedied its audit committee deficiency, demonstrating that governance gaps can be resolved swiftly. The aggregate data shows zero insider trading activity across all filings, suggesting management teams are not signaling conviction through personal transactions. No forward-looking guidance, capital allocation changes, or period-over-period financial comparisons were available in these event-driven 8-Ks, limiting trend analysis but amplifying the binary nature of the regulatory risks. The most critical development is CN Healthy Food Tech's July 23 appeal deadline, which will determine whether a full delisting and trading halt extension occurs, with material implications for shareholders of UCFI and UCFIW. The portfolio-level pattern is a clear uptick in Nasdaq enforcement actions against companies with governance gaps, low-priced stocks, and China-based operations facing CSRC scrutiny, creating both risk and potential catalyst-driven opportunities for active traders.

3 high priority 3 total filings
· daily

US SEC Trading Suspension Halt Orders — July 20, 2026

The July 20, 2026, trading suspension landscape is dominated by a cluster of small-cap companies facing Nasdaq/NYSE non-compliance, with two new filings (Smart Powerr Corp. and SES AI Corp) adding to the existing TEN Holdings situation. The most critical development is Smart Powerr Corp.'s imminent delisting and suspension on July 21, 2026, after failing to appeal a bid price deficiency, which will force a move to the OTCQB market with severe liquidity implications. SES AI Corp has received a similar NYSE notice but has a six-month cure period, providing a more manageable timeline, while TEN Holdings has temporarily resolved its equity deficiency through a $6.6M offering but remains under Nasdaq monitoring. The common thread is a liquidity crisis among micro-cap issuers, with all three companies showing deteriorating financial metrics and no insider buying to signal management confidence. The aggregate data reveals a pattern of regulatory fatigue, where companies exhaust compliance plans and appeal processes before facing final suspension orders.

3 high priority 3 total filings
· daily

US SEC Trading Suspension Halt Orders — July 17, 2026

On July 17, 2026, four Nasdaq-listed micro-cap companies disclosed imminent delisting or non-compliance risks, signaling a concentrated wave of regulatory enforcement against companies with deteriorating financial health. All four filings carry negative sentiment and high materiality (8-9/10), with common themes of insufficient stockholders' equity, collapsing market values, and sub-$1.00 bid prices. Period-over-period comparisons from the enriched data reveal that Dare Bioscience and Caring Brands both failed the same $2.5M stockholders' equity threshold, while Actuate Therapeutics saw its Market Value of Listed Securities (MVLS) fall below $50M starting June 1, 2026, and Fold Holdings breached the $1.00 minimum bid price for 30 consecutive days. No insider buying or capital allocation actions (dividends, buybacks) were reported across any of the four companies, underscoring severe financial distress and lack of management confidence. The most critical development is Caring Brands' imminent trading suspension deadline of July 24, 2026, if it fails to request a hearing by July 22, 2026—making it the highest-urgency situation. These filings collectively highlight a sector-wide purge of financially weak micro-caps from Nasdaq, with implications for liquidity risk, forced selling, and potential complete loss of equity value for shareholders.

4 high priority 4 total filings
· daily

US SEC Trading Suspension Halt Orders — July 16, 2026

The three filings in this trading suspensions stream present a mixed landscape for small-cap companies listed on US exchanges. Cycurion, Inc. faces imminent delisting from Nasdaq due to a prolonged bid price deficiency, with no compliance period available after a prior reverse split, creating a high-risk event for shareholders. TG-17, Inc. (Our Bond, Inc.) has received multiple non-compliance notifications for bid price and market value thresholds, but retains a 180-day cure period, offering a potential turnaround window. In contrast, SRx Health Solutions, Inc. (SRX Global Inc.) has resolved its NYSE American deficiency, marking a positive compliance event that removes delisting risk. Period-over-period comparisons are limited as filings are event-driven, but the divergence in outcomes—one delisting, one at risk, one compliant—highlights the binary nature of regulatory compliance for micro-cap equities. No insider trading, capital allocation, or forward-looking guidance data was provided in these filings, limiting trend analysis but emphasizing the criticality of exchange listing status as a catalyst.

3 high priority 3 total filings
· daily

US SEC Trading Suspension Halt Orders — July 15, 2026

All three filings in this digest center on Nasdaq non-compliance and imminent trading suspensions, creating a concentrated regulatory storm for micro-cap issuers on July 15, 2026. The most critical development is **SPAR Group's** definitive delisting on July 23, 2026, after shareholders rejected a reverse stock split, making its path to appeal the only remaining lifeline—a high-probability suspension event. **SemiLEDs** offers a contrasting narrative: after receiving a stockholders' equity deficiency notice in January 2026, the company submitted a compliance plan, saw equity improve to $3.1 million, and now believes it has regained compliance, though Nasdaq continues to monitor. **Triller Group** faces the tightest deadline, with a Panel exception requiring it to achieve a $1.00 closing bid for 20 consecutive business days by July 30, 2026—a binary catalyst given its history of repeated non-compliance and prior trading halt. Period-over-period data reveals no revenue or margin trends across these filings, as the filings are purely regulatory and non-financial; the core pattern is that all three companies faced equity or bid-price deficiencies, with SPAR Group being the most severe due to shareholder rejection of the cure. The aggregated insider activity is absent, capital allocation data is nil, and forward-looking guidance is limited to regulatory deadlines, underscoring that this stream is purely about listing viability rather than operational performance.

3 high priority 3 total filings
· daily

US SEC Trading Suspension Halt Orders — July 14, 2026

On July 14, 2026, two US-listed companies announced voluntary transfers of their stock listings between major exchanges, signaling a trend of proactive exchange migration rather than forced delistings. D-Wave Quantum Inc. (QBTS) is moving from the NYSE to Nasdaq, while Trinity Capital Inc. (TRIN) is transferring from Nasdaq to the NYSE and NYSE Texas. Both transfers are voluntary, approved by their boards, and involve no change in ticker symbols for the common stock, though Trinity's notes will see ticker adjustments. The moves are scheduled to take effect around July 27, 2026, with seamless trading continuity. No financial metrics, insider activity, or forward-looking guidance were disclosed in these filings, limiting the depth of quantitative trend analysis. The key takeaway is that both companies are seeking exchange environments they perceive as more advantageous, potentially for visibility, liquidity, or regulatory alignment, without any distress signals.

2 high priority 2 total filings
· daily

US SEC Trading Suspension Halt Orders — July 13, 2026

Three US-listed micro-cap companies received Nasdaq delisting or suspension notices on July 7-10, 2026, underscoring a severe liquidity and compliance crisis in the small-cap space. Pluri Inc. (PLUR) faces a market value deficiency with a cure period through January 4, 2027, while Actelis Networks (ASNS) has already been suspended and moved to OTCQB, and BNB Plus Corp. (BNBX) will be suspended July 14. All three filings carry negative sentiment and high materiality (9-10/10), with no insider buying, no forward guidance, and no capital allocation actions (dividends/buybacks) reported—indicating distressed balance sheets. The cluster of delistings within a single week suggests heightened regulatory scrutiny on minimum listing standards, particularly for companies with market caps below $35 million. Investors should monitor the OTCQB transition for potential price discovery dislocations and short-squeeze dynamics, while avoiding long exposure until compliance is restored.

3 high priority 3 total filings
· daily

US SEC Trading Suspension Halt Orders — July 10, 2026

On July 10, 2026, four micro-cap companies filed 8-Ks disclosing Nasdaq non-compliance, creating a concentrated wave of delisting risk in the small-cap space. All four filings are negative in sentiment, with materiality scores ranging from 8/10 to 9/10, signaling a systemic pattern of distress among low-priced equities. GeoVax Labs (GOVX) faces a stockholders' equity deficiency, while NanoVibronix (FEED), Lakeside Holding (LSH), and Mercer International (MERC) all violate the minimum $1.00 bid price rule. Notably, NanoVibronix is ineligible for the standard 180-day cure period due to a prior reverse split, making it the most acute risk. The concentration of these filings on a single day suggests a potential Nasdaq compliance sweep or broader market pressure on micro-cap stocks. No period-over-period financial trends, insider activity, or capital allocation data were available in these filings, limiting quantitative cross-comparison but highlighting the purely regulatory nature of the risk. The key market implication is a potential wave of delistings that could compress valuations across the micro-cap sector and trigger forced selling by index funds.

4 high priority 4 total filings
· daily

US SEC Trading Suspension Halt Orders — July 09, 2026

All four filings in this digest highlight micro-cap companies facing imminent delisting or trading suspension from US exchanges (NASDAQ and NYSE American), driven by non-compliance with minimum bid price and shareholders' equity requirements. The cluster of events on July 2-9, 2026, signals a potential sector-wide liquidity and valuation crisis among small-cap issuers, with no positive period-over-period trends or insider buying to offset the negative outlook. The most critical development is the immediate delisting risk for Prairie Operating Co. if its stock trades at or below $0.10 for ten consecutive days, representing a binary event. Across the portfolio, all companies are in the 'cure period' with no forward-looking guidance or capital allocation improvements, suggesting a high probability of eventual suspension or delisting. The aggregate market implication is a bearish signal for micro-cap equities, as regulatory enforcement appears to be tightening on chronically non-compliant issuers.

4 high priority 4 total filings
· daily

US SEC Trading Suspension Halt Orders — July 08, 2026

The single filing in this stream, from Borealis Foods Inc., presents a high-risk delisting scenario on the Nasdaq Capital Market. The company received a deficiency notice for failing to meet the minimum Market Value of Listed Securities (MVLS) requirement of $35 million, with a 180-day cure period ending December 29, 2026. Critically, Borealis also fails to meet alternative listing standards based on stockholders' equity or net income, significantly narrowing its path to compliance. The negative sentiment and high materiality score (9/10) underscore the existential threat to the company's public listing, with a delisting of common shares automatically triggering the delisting of its warrants (BRLSW). No period-over-period comparisons, insider activity, or forward-looking guidance were provided in the enriched data, limiting trend analysis but amplifying the binary risk of the situation. The lack of any positive catalysts or capital allocation actions (e.g., buybacks) suggests management is in a reactive, rather than proactive, position.

1 high priority 1 total filings
· daily

US SEC Trading Suspension Halt Orders — July 07, 2026

The single filing for DevvStream Corp. (DEVS) dominates an otherwise silent session for US trading suspensions, delistings, and regulatory halts. The company entered a definitive Securities Purchase Agreement (SPA) for a $6.0M investment, superseding a prior term sheet, with only $1.5M funded to date and the remaining $4.5M due by September 30, 2026. The transaction is contingent on closing a business combination agreement (BCA), creating a binary catalyst with material execution risk. The mixed sentiment and high materiality (8/10) reflect the precarious funding structure and the potential for a dilutive or preferential-share outcome if the BCA fails. No period-over-period comparisons, insider activity, or capital allocation data were available, limiting trend analysis but highlighting a single high-stakes corporate event.

1 high priority 1 total filings
· daily

US SEC Trading Suspension Halt Orders — July 06, 2026

All three filings (CISO Global, CytoSorbents, Polar Power) involve Nasdaq non-compliance notices, creating a concentrated cluster of delisting risks in the micro-cap and small-cap space. Period-over-period data reveals severe financial deterioration: Polar Power reported only $144,000 in stockholders' equity against a $2.5 million requirement, while CytoSorbents failed the $35 million market value test. CISO Global faces a bid price deficiency. The common deadline of December 28, 2026, for CISO and CytoSorbents suggests a potential wave of delistings in late 2026. Insider activity data is absent across all filings, indicating a lack of management confidence or inability to signal conviction. Capital allocation is non-existent (no dividends, buybacks, or splits), reflecting distressed financial health. The sector theme is a 'Nasdaq Compliance Crisis' for micro-caps, with aggregate equity deficiency of ~$2.36 million and market value shortfall of unknown magnitude. The most critical development is the high probability of at least one delisting by year-end 2026, with Polar Power at highest immediate risk (October 28 deadline).

3 high priority 3 total filings
· daily

US SEC Trading Suspension Halt Orders — July 02, 2026

The digest covers 7 filings related to trading suspensions and delistings, all from Nasdaq-listed companies facing compliance issues or voluntary termination. Six companies received deficiency notices for failing to meet the $1.00 minimum bid price requirement, with compliance deadlines set for December 28, 2026. Boxlight Corp received a delisting notice for failing to meet the $2.5 million stockholders' equity requirement and plans to appeal. MV Oil Trust voluntarily delisted from the NYSE due to trust dissolution, with final distribution on July 24, 2026. The predominant theme is the risk of delisting for small-cap companies, with many considering reverse stock splits as a remedy. No insider trading activity, revenue growth trends, or capital allocation changes were reported in these filings, limiting quantitative comparisons. The most critical development is Boxlight's imminent delisting risk, given its failure to meet equity standards and reliance on uncertain financing.

7 high priority 7 total filings
· daily

US SEC Trading Suspension Halt Orders — July 01, 2026

This digest covers three US-listed companies facing trading suspensions or delistings in July 2026, revealing a concentrated wave of corporate distress and restructuring. InnSuites Hospitality Trust (IHT) received a NYSE American delisting notice due to a stockholders' deficit of ~$(921,921) and recurring net losses, with a compliance plan due July 24, 2026. Stratus Properties Inc. (STRS) is voluntarily delisting from Nasdaq as part of a complete liquidation and dissolution plan, with an initial $5.00 per share liquidating distribution declared. ESS Tech, Inc. (GWH) faces NYSE delisting of its Public Warrants (GWH.W) due to 'abnormally low' trading prices, though its common stock remains listed. Period-over-period data was not provided in the enriched filings, limiting trend analysis, but the filings collectively signal heightened regulatory scrutiny and shareholder value destruction across small-cap and micro-cap equities. Insider trading activity and forward-looking guidance were absent from the enriched data, but the scheduled events (compliance plan deadline, delisting effective date, distribution record date) create actionable catalyst timelines. The most critical development is the voluntary liquidation of Stratus Properties, which offers a near-term cash distribution opportunity but carries significant risk of further losses.

3 high priority 3 total filings
· daily

US SEC Trading Suspension Halt Orders — June 30, 2026

This digest covers three Nasdaq-listed companies facing significant regulatory and compliance challenges, all within the trading suspension/delisting risk spectrum. Gulf Resources (GURE) and SolarMax Technology (SMXT) are newly flagged for non-compliance, while HCW Biologics (HCW) has narrowly avoided immediate delisting but remains under intense scrutiny. A key theme is the compounding risk for SMXT, which now faces two separate listing deficiencies (market value and bid price), signaling a high probability of eventual delisting. GURE's delinquency in filing critical periodic reports (10-K and 10-Q) points to deep operational and disclosure issues. HCW's reprieve is conditional and temporary, with a Mandatory Panel Monitor through mid-2027. There are no positive period-over-period trends, insider activity, or capital allocation events in these filings; the focus is entirely on regulatory risk and survival. The aggregate picture is one of heightened delisting pressure across micro-cap names, with no clear path to compliance for two of the three companies.

3 high priority 3 total filings
· daily

US SEC Trading Suspension Halt Orders — June 26, 2026

The three filings in this trading suspension digest present a starkly divided micro-cap landscape on June 26, 2026. Two companies (Upexi and Matinas BioPharma) are actively fighting for their exchange listings, while a third (Outlook Therapeutics) has successfully resolved its delisting threat. The most critical development is the high materiality (9/10) of all three events, indicating significant binary risk for investors. Upexi faces a Nasdaq delisting notice due to a massive $187M convertible note issuance without shareholder approval, yet paradoxically gained inclusion in the Russell Microcap Index. Matinas BioPharma received a second NYSE American non-compliance notice with stockholders' equity at just $3.02M, but secured a long compliance plan through October 2027. Outlook Therapeutics provides a positive counterpoint, having regained Nasdaq compliance on bid price after a four-month struggle. The common thread is that all three companies are navigating severe financial distress or governance issues, with regulatory deadlines creating near-term catalysts. No period-over-period revenue or margin trends were available in these filings, as the focus was on listing compliance rather than operational performance.

3 high priority 3 total filings
· daily

US SEC Trading Suspension Halt Orders — June 26, 2026

The three filings in this digest on trading suspensions, delistings, and regulatory halts reveal a stark bifurcation in micro-cap healthcare and technology companies. Two companies (Upexi and Matinas BioPharma) are actively fighting non-compliance, while one (Outlook Therapeutics) has successfully reversed its delisting risk. The key trend is the high frequency of non-compliance events tied to convertible note structures (Upexi) and sustained negative equity positions (Matinas), which are typical distress signals for micro-caps. Critically, enriched period-over-period data is absent from these filings, as they are event-driven 8-K filings rather than periodic reports; however, forward-looking data on compliance deadlines, insider trading (unavailable), and capital allocation (unavailable) still provides a high-stakes outlook. The most material development is the Russell Microcap Index addition for Upexi, which injects a positive catalyst into an otherwise dire delisting scenario. The sector theme is clear: small-cap biotech and tech firms face a tightening regulatory and capital environment, forcing a high rate of 'penny stock' distress.

3 high priority 3 total filings
· daily

US SEC Trading Suspension Halt Orders — June 25, 2026

The two filings today represent a stark contrast in trading suspension/delisting outcomes within the Nasdaq ecosystem. Global Interactive Technologies (GITS) successfully resolved its compliance deficiency, confirming a de-listing risk reversal that provides a clean bill of health for its listing status. Conversely, Heron Therapeutics (HRTX) faces a new, acute price-based delisting threat, with its stock trading below the $1.00 minimum bid threshold. The key divergence lies in the root cause: GITS faced a procedural (filing) issue which was cured, while HRTX faces a fundamental market valuation challenge. The absence of strong insider buying or operational catalysts at Heron Therapeutics amplifies the risk of a forced reverse stock split and potential eventual delisting if the stock price fails to recover. The patterns highlight that while procedural compliance can be restored through administrative action, price-based non-compliance requires market-driven solutions, making it a more challenging obstacle.

2 high priority 2 total filings